Myositis, also known as idiopathic inflammatory myopathy, is a group of complex autoimmune diseases in which the immune system attacks muscle tissue, causing inflammation, weakness, skin rash, and other symptoms, which can lead to life-threatening complications. Because these conditions are relatively rare and heterogenous, researchers often need to combine data from multiple studies and centers to conduct meaningful research. Although recent progress has been made in developing validated myosotis outcome measures, differences in how data are collected and recorded remain a critical challenge.
A new study addresses this gap by developing standardized, computable Common Data Elements (CDEs) for myositis research that are aligned with the NIH CDE framework. The effort was led by the National Institute of Environmental Health Sciences (NIEHS) and the National Library of Medicine (NLM), with support from the NIH Office of Autoimmune Disease Research (OADR-ORWH) and the Office of Data Science Strategy (ODSS).
The research team began by analyzing data dictionaries from existing myositis registries. Using an open-source tool called Linked data Modeling Language (LinkML), they created structured, machine-readable CDEs that can be easily shared, reused, validated, and integrated with existing data standards such as Observational Medical Outcomes Partnership (OMOP) and Unified Medical Language System (UMLS). The team also introduced design strategies to bundle related data elements, making the system more efficient and easier to scale.
To ensure the CDEs were both scientifically rigorous and practical, the team convened an international panel of experts, including clinicians, researchers, data scientists, and patient representatives. Through a series of conferences and a structured, multi-step consensus process, participants reviewed, refined, and voted on the proposed CDEs. This effort resulted in 852 consensus-based CDEs across 27 myositis-related forms, covering key areas such as disease activity, damage, functional assessments, classification criteria, and patient-reported outcomes. These CDEs have been endorsed by the NIH CDE Governance Committee and are now available through the NIH CDE Repository. Investigators can pair them with REDCap tools and other structured data collection resources to facilitate adoption in research and clinical trials.
In addition to advancing myositis research, this work established a standardized workflow and presented a scalable model for CDE development across other autoimmune diseases, demonstrating how combining domain expertise, patient input, and modern data science can produce interoperable research infrastructure for advancing the research of rare diseases, cross-study comparisons and multi-center collaborations.
Beyond myositis, OADR, NLM, and ODSS have recently published a commentary highlighting the broader challenges of fragmented data across the autoimmune disease research portfolio, emphasizing the importance of addressing interoperability across existing datasets and studies. The commentary emphasized the importance of CDEs as a foundational approach to improve data quality, enable data sharing, and support more reliable and reproducible research. Reflecting congressional direction to strengthen coordination and advance data standards in autoimmune disease research, and aligning with priorities outlined in the NIH-Wide Strategic Plan for Autoimmune Disease Research, the commentary reviewed ongoing NIH efforts and called on the community to engage in collaborative, consensus-driven CDE development. Investigators were encouraged to leverage funding mechanisms such as the NIH Research Conference Grant (R13) to support these efforts, with the goal of building a more connected, interoperable, and impactful research ecosystem. For more information or to discuss CDE development in autoimmune disease research, please contact [email protected].